Mojisola Adeyeye


Mojisola Adeyeye

Director General, National Agency for Food and Drug Administration and Control (NAFDAC) Nigeria

Prof Moji Adeyeye is the Director General of National Agency for Food and Drug Administration and Control (NAFDAC) where she has added strong governance structure and regulatory strengthening to NAFDAC through disciplined and motivating workforce, updating of regulations and guidelines, strengthening the local pharmaceutical companies through international best practices, and encouraging local production. She has brought NAFDAC from insolvency to solvency. She refocused the Agency through Quality Management System approach and WHO Global Benchmarking to be Standard Operating Procedure-driven organization that has embraced international standards and best practices. This has resulted in attainment of ISO 9001-2015 in 2019, and WHO Maturity Level 3 (ISO 9004) in 2022, recognition as a well-functioning Agency in many regulatory functions such Pharmacovigilance and Clinical Trials. She changed the culture of NAFDAC to Customer-focused and Agency-minded establishment in order to safeguard the health of the nation. The Director General is keenly involved in the Lot Release, Post-Approval Safety Monitoring, and Traceability of COVID-19 vaccines, that is focused on visibility of COVID-19 Vaccines Supply Chain using GS1-driven Technology nationally and continentally. She has initiated research collaboration with several institutions as a means of increasing staff competency as part of improving regulatory research. Prof Adeyeye graduated from University of Nigeria, Nsukka, Nigeria with a B. Pharm degree in 1976, a MS, and PhD from the University of Georgia, Athens, GA, in Industrial Pharmacy, in 1985 and 1988 respectively.  She started her career at the University of Puerto Rico as Assistant Professor and moved on to Duquesne University in Pittsburgh, PA, USA where she spent 21 years during which she went through the academic career advancement to full Professor of Pharmaceutics and Drug Product Evaluation.  She moved on take on the position of Founding Chair of a new department of Biopharmaceutical Sciences in the then new College of Pharmacy, Roosevelt University in Chicago during which she hired 12 new faculty and staff, built four research laboratories, and led a thriving research faculty in the different emphases. Her research interests include quality-by-design (QbD) early phase development and manufacturing of solid, semisolid and liquid dosage forms, including Investigation New Drug Application (IND)-based late phase manufacturing.  She is an expert in pharmaceutical research and development (R&D), bench-to-bedside translational clinical  research and regulatory science. She has mentored over 15 PhD and M.S candidates co-advised 18 graduate students as research committee member.  She retired in 2017/2018 to start her own company Elim Pediatric Pharmaceuticals, but that was short-lived because she was appointed few months after as Director General, National Agency for Food and Drug Administration and Control (NAFDAC) Nigeria, a position she is holding to date.